

Ginsenoside Rg₁ protects neurons from hypoxic–ischemic injury possibly by inhibiting Ca²⁺ influx through NMDA receptors and L-type voltage-dependent Ca²⁺ channels

Yun-Feng Zhang^{a,b}, Xing-Juan Fan^{a,b}, Xia Li^a, Liang-Liang Peng^a, Guo-Hua Wang^a, Kai-Fu Ke^b, Zheng-Lin Jiang^{a,*}

^a Department of Neuroparmacology, Institute of Nautical Medicine, Nantong University, 19 Qixiu Road, Nantong, Jiangsu, 226001, China

^b Department of Neurology, Affiliated Hospital, Nantong University, 19 Qixiu Road, Nantong, Jiangsu 226001, China

Received 3 August 2007; received in revised form 2 December 2007; accepted 16 December 2007

Available online 14 February 2008

Abstract

The purpose of this study is to assess the neuroprotective effect of Rg₁, a ginsenoside. We measured cell viability and lactate dehydrogenase (LDH) release from primary culture of rat hippocampal neurons and electrical activities in hippocampal slices of rats, before and after the neurons were deprived of oxygen and glucose. In addition, cerebral damage was evaluated with magnetic resonance imaging after middle cerebral artery was occluded transiently. Nissl staining was used for histological observation and immunohistochemistry analysis for activated caspase-3 expression of the brain. Furthermore, calcium influx was measured with laser confocal microscopy in neurons perfused with KCl (50 mM) or *N*-methyl-D-aspartate (NMDA, 1 mM), or deprived of oxygen and glucose. The influences of ginsenoside Rg₁ on these parameters were determined simultaneously. We found that treatment of Rg₁: 1) increased the neuronal viability; 2) promoted the recovery of electrical activity in hippocampal slices; 3) reduced the release of LDH, cerebral damage area, neuronal loss and expression of caspase-3; and 4) inhibited calcium influx induced by NMDA, KCl or oxygen/glucose deprivation. However, the protective effect of Rg₁ was blocked by mifepristone, an antagonist of glucocorticoid receptors. Taken together, these results suggest that ginsenoside Rg₁ can reduce neuronal death, including apoptotic cell death, induced by hypoxic–ischemic insults. This neuroprotective effect is probably mediated by the activation of glucocorticoid receptors, and by the inhibition of calcium influx through NMDA receptors and L-type voltage-dependent Ca²⁺ channels and the resultant reduction of intracellular free Ca²⁺.
© 2008 Published by Elsevier B.V.

Keywords: Ginsenoside Rg₁; Neuroprotection; Focal cerebral ischemia/reperfusion; NMDA receptors; L-type voltage-dependent calcium channels; Calcium overload

1. Introduction

Although ischemic cerebral stroke has become one of the leading causes of human death and disability in the world, the treatment of stroke remains much unsatisfactory. Almost all neuroprotective agents proved to be promising in animal stroke experiments were disappointing in clinical human trials (Cheng et al., 2004; Curry, 2003; Gladstone et al., 2002; Jonas et al., 2001), but the recent success of “Fast-Mg²⁺” therapy (Saver et al.,

2004) has stimulated our interests in searching for new neuroprotective agents for cerebral stroke management.

Panax ginseng C.A. Meyer (Araliaceae), a well-known herb in Traditional Chinese Medicine has been used widely for thousands of years, and ginsenosides or ginseng saponins are popularly considered as one of the principal bioactive ingredients (Kiefer and Pantuso, 2003). Up to now, over thirty different ginsenosides have been identified from ginseng. They are classified into three subclasses: panaxadiol, panaxatriol and oleanolic acid type ginsenosides (Attele et al., 1999). Ginsenoside Rg₁ belongs to the panaxatriol ginsenosides family. Growing evidence indicates a neuroprotective effect of total saponins or a part of single ginsenosides in several experimental

* Corresponding author. Tel./fax: +86 513 85051796.

E-mail address: jiangzl@ntu.edu.cn (Z.-L. Jiang).

models such as excitotoxicity insults, traumatic brain injury and cerebral ischemia (Ji et al., 2005; Van Kampen et al., 2003; Kim et al., 1998, 2007; Lee et al., 2002; Leung et al., 2007; Liao et al., 2002; Lim et al., 1997; Tian et al., 2005; Wen et al., 1996; Zhang and Liu, 1996). To search for effective neuroprotective agents, we have compared the neuroprotective effects of 9 single ginsenosides (Rb₁, Rb₃, Rd, Re, Rg₁, Rg₂, Rh₁, Rh₂, F₁₁) in hippocampal slices, and found that Rb₁, Rb₃, Rg₁, Rh₂, and F₁₁ could protect hippocampal neurons and alleviate neuronal injury induced by oxygen/glucose deprivation (Jiang et al., 2000, 2001; Jiang and Jiang, 2003). The neuroprotective effect of ginsenoside Rg₁ has been investigated recently by other researchers in several cell-damaging models (Chen et al., 2003; Leung et al., 2007; Li et al., 1997; Li and Zhang, 1997; Liao et al., 2002; Liu and Zhang, 1995; Rudakewich et al., 2001), but less in hypoxic–ischemic conditions. Moreover, the mechanisms underlying the neuroprotective effect of Rg₁ are still unclear.

A number of reports have shown that ginsenosides could modulate the functions of many receptors and ion channels on neurons, including *N*-methyl-D-aspartate (NMDA) receptors (Kim et al., 2002, 2004; Kim and Rhim, 2004; Lee et al., 2006a,b) and Ca²⁺ channels (Rhim et al., 2002). Due to the central involvement of the activation of NMDA receptors and calcium overload in ischemic brain injury (Berliocchi et al., 2005), the current investigation was designed mainly to assess the inhibitory influence of ginsenoside Rg₁ on Ca²⁺ influx evoked by oxygen/glucose deprivation and potential involvements of NMDA receptors and L-type voltage-dependent Ca²⁺ channels.

2. Materials and methods

2.1. Animals and chemicals

Sprague–Dawley rats were obtained from the Experimental Animal Center of Nantong University, Nantong, China. All procedures used in this study were in accordance with our institutional guidelines, which comply with international rules and policies. Ginsenoside Rg₁, extracted from the stem and leaf of Jilin *P. ginseng*, was purchased from the Department of Organic Chemistry, Medical School of Jilin University, Changchun, China, and the purity (HPLC analysis) was 98.2% (Lot # 20060208). Common inorganic salts were purchased in China, culture mediums were purchased from Invitrogen Corporation (Carlsbad, USA), Fluo 3-AM from Dojindo Laboratories (Kumamoto, Japan), and 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) from BDH Chemicals Ltd. (Poole, England). Mifepristone (11β-(4-dimethylamino)phenyl-17β-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one, RU486), cytosine β-D-arabinofuranoside, sodium dodecylsulphate, and other chemicals except those indicated elsewhere were purchased from Sigma-Aldrich Corporation (Saint Louis, USA).

2.2. Cell culture

Hippocampi were removed from embryonic rats (E17–18). Briefly, hippocampal cells were isolated and plated immediately

unto 96- and 24-well plates. These plates were coated with poly-L-lysine overnight prior to the experiment. Cells were grown in the plating medium with 85% high glucose Dulbecco's Minimum Essential Medium (DMEM, 12100-046), 15% fetal bovine serum (Hyclone, Logan, USA), and 10⁶ U/l penicillin–streptomycin. Six hours later, the plating medium was changed with the feeding medium with 98% neurobasal medium (21103-049), 2% B27 (17504-044), 2 mM glutamine, and 10⁶ U/l penicillin–streptomycin. The day of plating was counted as day-in-vitro 0. On day-in-vitro 3, cytosine β-D-arabinofuranoside (5 μM) was added to suppress the proliferation of glial cells. The feeding medium was changed every 3 days. Cultures were maintained in a 5% CO₂ incubator at 37 °C.

2.3. Hippocampal slice preparation and recording of orthodromic population spikes

Male rats (120–150 g body weight) were anesthetized with ether and then sacrificed by decapitation. Each brain was rapidly removed and dissected in cold (0–4 °C) artificial cerebrospinal fluid (aCSF) containing (in mM) NaCl 124, NaHCO₃ 25.7, KCl 3.3, MgSO₄ 2.4, CaCl₂ 2.4, NaH₂PO₄ 1.24, Glucose 10.0, pH 7.35–7.45, and saturated with 95% O₂–5% CO₂ (oxygenated). Transverse hippocampal slice, 400 μm thick, was made with a vibroslicer (MA 752, Campden Instruments Ltd., Loughborough, England) and placed into a recording well with temperature maintained at 32±0.5 °C, and the upper surface of the slice was submerged 2 mm under the oxygenated aCSF. The slice was continuously perfused with oxygenated aCSF at a flow rate of 1.5–2 ml/min. One hour later, the orthodromic response in area CA₁ of each slice was elicited by stimulating CA₃ Schaffer collaterals at a frequency of 0.1 Hz through a bipolar electrode with square wave pulses of 0.1 ms duration and 0.2–0.7 mA intensity. Orthodromic population spikes were recorded in the CA₁ pyramidal layer of the hippocampal slice at a depth of about 0.1 mm under the cut surface with a glass microelectrode. The glass microelectrode had a resistance of 3–5 MΩ when filled with 2 mM NaCl solution. Orthodromic population spikes were recorded by an X–Y recorder, each trace was the average of 4 responses. Only the slice with the orthodromic population spike amplitude of 3 mV or greater was utilized for further testing.

2.4. Oxygen/glucose deprivation

Oxygen/glucose deprivation was carried out in three experiments: two measurements of cell damage and Ca²⁺ influx in cultured hippocampal neurons and the recording of electrical activity in hippocampal slices. For the measurement of cell damage, primarily cultured hippocampal neurons on days-in-vitro 12–13 were rinsed twice with extracellular solution containing (in mM): NaCl 145, KCl 3, HEPES 10, CaCl₂·2H₂O 3, MgCl₂·6H₂O 2, glucose 8, incubated in glucose-free DMEM (11966-025) at 37 °C and placed in an incubator containing 94% N₂, 5% CO₂ and 1% O₂ for 5 h. The neurons were then fed with high glucose DMEM, and returned to the normal incubator for a 24-h recovery. Those neurons for control underwent the same procedure except the oxygen/glucose

deprivation treatment. In addition, oxygen and glucose were deprived for 14 min and 10 min respectively, during the recording of electrical activity in hippocampal slices and the measurement of Ca^{2+} influx in cultured hippocampal neurons, by perfusion with aCSF and extracellular solution saturated with 95% N_2 –5% CO_2 . Glucose in these two solutions was substituted with sucrose.

2.5. Measurements of cell damage

Cell viability was assessed with the MTT method. Briefly, 24 h after the oxygen/glucose deprivation treatment, the culture medium was removed from the 96-well plate, the neurons were washed twice with phosphate-buffered saline, and the MTT solution of 25 μl was then added into each well (final concentration 1 g/l). Following incubation at 37 °C for 4 h, 100 μl of 20% sodium dodecylsulphate solution (dissolved in dimethylformamide) was mixed into each well to dissolve the resultant dark blue crystal for 20 h. Absorbance of each well was measured at a wavelength of 570 nm (OD 570) with the Universal Microplate Reader (ELx 800, BioTek instruments, Inc., Winooski, USA).

Neuronal damage was also evaluated by measurement of lactate dehydrogenase (LDH) released into the culture medium. LDH activity was determined according to the protocol of an LDH kit (Jiancheng Bioengineering Institute, Nanjing, China). At the end of various treatments, 0.4 ml of medium was mixed with 1.3 ml nicotinamide adenine dinucleotide (NADH) solution and 1.3 ml sodium pyruvate solution. Both agents were dissolved in potassium phosphate buffer (100 mM K_2HPO_4 , adjusted to pH 7.5 with KH_2PO_4). The mixed solution was immediately assayed with a UV-2450 visible spectrophotometer (Shimadzu Corporation, Kyoto, Japan) by monitoring the conversion of NADH to NAD at 340 nm at 37 °C, coupled with the reduction of pyruvate to lactate. LDH activity is expressed as units/ml, with one unit of activity representing the amount of LDH that causes a decrease of 0.001 absorbance unit of NADH per minute in the presence of sodium pyruvate.

2.6. Surgery of middle cerebral artery occlusion

Male rats (230–270 g body weight) were anesthetized using 2 ml enflurane in an ether jar, and maintained with 10% chloral hydrate (400 mg/kg, i.p.). The middle cerebral artery was occluded with a 4-0 silicone-coated nylon suture by surgical operation as described by Gerriets et al. (2003). Reperfusion was induced 2 h after middle cerebral artery occlusion by filament withdrawal. Sham-operated animals were subjected to the same surgical procedure, but the suture was not advanced beyond the internal carotid bifurcation. Rectal temperature of rats was maintained at 37 °C throughout the anesthetic period including the surgical procedures using a temperature-regulated heating pad. After revival from anesthesia, animals were housed back at room temperature (24 ± 1 °C), with free access to food and tap water.

Neurological evaluation was performed at both 2 h and 24 h after reperfusion of the middle cerebral artery and scored on a 6-point scale: 0, no neurological deficit; 1, failure to extend left

forepaw fully; 2, circling to the left; 3, inability to bear weight on the left; 4, no spontaneous walking with depressed level of consciousness; and 5, death.

2.7. Magnetic resonance imaging (MRI)

A subgroup of rats which were subjected to middle cerebral artery occlusion was examined with MRI in a 3.0 T scanner (Signa Excite HD 3.0T, GE Healthcare, Connecticut, USA). An actively shielded gradient coil with a 120-cm inner diameter driven by the standard gradient power supply was applied. In this configuration, 180 mT/m could be reached in 180 ms. As a rapid frequency coil, we adopted a home-made birdcage resonator with a 125-mm inner diameter. MRI examination was performed at 4 h and on days 1, 2 and 5 after middle cerebral artery occlusion, respectively. For each animal, a T_2 -weighted MRI with a FRFSE sequence (repetition time=5200 ms, echo time=85 ms, number of averages=2, field of view=4.0 cm×4.0 cm, matrix=320×288, 6 slices, slice thickness=2 mm) was performed. Image data of T_2 -weighted MRI were analyzed with Image-Pro Plus 5.1. We calculated the damage size as described by Heiland et al. (1997). The ischemic damage on T_2 -weighted MRI was defined as hyperintense areas on the image with the highest T_2 weighting (echo time=96 ms). The lesion area was subdivided into cortical and subcortical parts according to neuroanatomic landmarks.

2.8. Nissl staining and immunohistochemistry

After 2-h ischemia and 22-h reperfusion, rats were anesthetized with 10% chloral hydrate (400 mg/kg, i.p.) and perfused with 200 ml saline and subsequently with 4% paraformaldehyde in 0.1 M phosphate buffer saline (pH 7.4). Rat brains were then removed and post-fixed for 24 h in the same fixative. The post-fixed brains were dry-protected in 25% sucrose in phosphate-buffered saline.

For Nissl staining, the brain tissue was then sectioned coronally 20 μm in thickness from 2.3 mm posterior to the bregma with a cryostat slicer (CM1900, LAICA, Bensheim, Germany). Six sections were collected by selecting one slice from every 6 slices. These sections were mounted with neutral balata and blotted onto slides before being processed through different baths in the following order (and time): chloroform (30 min), acetone (15 min), 100% ethanol (30 s), 95% ethanol (30 s), 70% ethanol (30 s), distilled water (30 s, twice), cresyl violet (20 min), distilled water (30 s, three times), 70% ethanol (1 min), 95% ethanol (1 min), 100% ethanol (1 min), chloroform (5 min), differentiator (95% ethanol, added glacial acetic acid till pH was 4.1) (6 min), 95% ethanol (2 min), 100% ethanol (3 min, twice), xylene (2 min), xylene (3 min, twice), and then covered with a coverslip.

For immunohistochemical assay of neuronal expression of the activated caspase-3, the rat brain was immersed in paraffin and then embedded. The paraffin-embedded brain was coronally sectioned 5 μm in thickness from 2.3 mm posterior to the bregma. Six sections were collected by selecting one from every 10 slices. As the primary antibody, the rabbit polyclonal antibody against cleaved caspase-3 (Asp175, Cell Signaling Technology Inc.,




Fig. 1. Ginsenoside Rg₁ elevates cell viability and reduces LDH release of cultured hippocampal neurons subjected to oxygen/glucose deprivation (OGD). A, cell viability ($n=12$). B, release of LDH ($n=6$). RU486, an antagonist of glucocorticoid receptors significantly attenuated the effect of Rg₁. *, $P<0.05$, OGD+Rg₁ vs OGD; #, $P<0.05$, vs that of Rg₁ at 1 nM; Δ, $P<0.05$, vs that of Rg₁ without RU486. Note that RU486 (10 μM) itself did not induce significant changes in cell viability and LDH release in OGD-treated neurons.

Boston, USA) was used at 1:100 dilution. The secondary antibody was biotin-conjugated goat anti-rabbit IgG (Chemicon International, Temecula, CA, USA). An ABC kit (Zhongshan Biotechnology Company, Beijing, China) was adopted to localize the secondary antibody. Finally, a diaminobenzidine kit (Zhongshan Biotechnology Company) was applied to visualize the catalyzed peroxidase-reaction product. Simultaneously, negative control was performed without the primary antibody.

2.9. Intracellular Ca²⁺ imaging

For intracellular free Ca²⁺ imaging, the acetoxymethyl-ester form of Fluo 3 (Fluo 3-AM) was used as a fluorescent Ca²⁺ indicator. The cultured hippocampal neurons on day-in-vitro 13 were loaded with 5 μM Fluo 3-AM, which was added in extracellular solution for 45 min at 37 °C. After being washed three times with normal extracellular solution, the neurons were incubated at 37 °C for another 30 min to complete the deesterification of Fluo 3-AM. The intensity of fluorescence with the excitation wavelength at 485 nm and emission wavelength at 525 nm was recorded every 10 s using a laser scanning confocal microscope (TCS SP2, Leica Microsystems, Heidelberg, Germany). All image data were collected and analyzed with the Leica Control software of the microscope. The increase of intracellular free Ca²⁺ was determined according to the following equation: Ca²⁺ influx (%) = $(F_{525} - F_{\text{base}, 525}) / F_{\text{base}, 525} \times 100$, where F_{525} is the fluorescence intensity we measured after each treatment, and $F_{\text{base}, 525}$ the basal

fluorescence intensity. High extracellular K⁺ solution containing (in mM): 98 NaCl, 50 KCl, 10 HEPES, 3 CaCl₂·2H₂O, 2 MgCl₂·6H₂O, 8 glucose was used for the induction of Ca²⁺ influx through the L-type Ca²⁺ channels.

2.10. Application of Rg₁ and RU486

Ginsenoside Rg₁ was dissolved in dimethyl sulphoxide as a concentrated stock, diluted with normal saline, extracellular solution or culture medium as needed just before use. In *in vivo* experiments, Rg₁ was given intraperitoneally (20 mg/kg) 1 h before middle cerebral artery occlusion and repeated every 12 h until each experiment was completed. In *in vitro* experiments, Rg₁ was applied to cultured hippocampal neurons simultaneously with high KCl or NMDA-containing extracellular solution, or immediately before oxygen/glucose deprivation. For hippocampal slices, Rg₁ was administered to bath solution 10 min before oxygen/glucose deprivation and maintained until 15 min after the recovery of oxygen/glucose supply. RU486, an antagonist of glucocorticoid receptors, was also dissolved in dimethyl sulphoxide as a stock, diluted with cell culture medium before application. RU486 (final concentration of 10 μM) was administered to neurons 30 min before oxygen/glucose deprivation. The final concentration of dimethyl sulphoxide was 0.1%.




Fig. 2. Ginsenoside Rg₁ facilitates the recovery of orthodromic population spike (OPS, the large and downward wave (←), Fig. 2A) in CA₁ area of rat hippocampal slices after oxygen/glucose deprivation (OGD). A, examples of OPS recorded in Rg₁-treated slice and paired control slice at the time indicated. During OGD, OPS decreased (at 7 min, ↑), disappeared (at 10 min), and then reappeared with reduced amplitude (at 12 min, ↑) in the control slice. This reappeared OPS is termed as hypoxic injury potential (HIP). HIP disappeared (at 14 min) rapidly after its occurrence in the control slice. OPS did not recover in the control slice (1 h after OGD). With application of Rg₁, OPS was reduced (1 min before OGD, →), did not disappear during OGD, and recovered completely (1 h after OGD). Scale bar was shown at the right lower side. B, mean values of control group ($n=7$) and Rg₁-treated groups ($n=6$). *, $P<0.05$ vs control.




Fig. 3. Ginsenoside Rg₁ improves the neurological behavior and decreases the cerebral damage size on MRI at different time after middle cerebral artery occlusion (MCAO). A, Rg₁ treatment significantly decreased the neurology deficit score of rats ($n=16$) 24 h after MCAO. B, Rg₁ treatment significantly reduced cortical damage size of rat brain at all time points ($n=4$). *, $P<0.05$, vs MCAO; $^{\Delta}$, $P<0.05$, vs that at 4 h.

2.11. Statistical analysis

All values are presented as mean \pm S.D. Data were analyzed with Student's t -test or analysis of variance for two or more than two groups, respectively. Differences were considered statistically significant at a level of $P<0.05$.

3. Results

3.1. Protective effect of Rg₁ on cultured hippocampal neurons subjected to oxygen/glucose deprivation

We firstly evaluated the protective effect of Rg₁ by comparing the cell viability and LDH release. After oxygen/glucose deprivation insult, the cell viability of the cultured hippocampal neurons was decreased significantly to $77.2 \pm 3.6\%$ of control ($n=12$, $P<0.05$, Fig. 1A), and LDH release was increased from 34.9 ± 5.6 in control to 276.7 ± 74.4 U/ml/min ($n=6$, $P<0.05$, Fig. 1B). These changes were attenuated prominently by the treatment of ginsenoside Rg₁ (at the concentration range from 10 nM to 100 μ M, $P<0.05$). An application of Rg₁ (100 μ M) significantly improved the cell viability to $94.7 \pm 2.4\%$ ($n=12$, $P<0.05$, Fig. 1A), and reduced LDH release to 105.5 ± 17.0 U/ml/min ($n=6$, $P<0.05$, Fig. 1B). However, the effects of Rg₁ were significantly blunted by the pretreatment of RU486, an antagonist of glucocorticoid receptors (right columns in Fig. 1A and B). Specifically, addition of RU486 reduced the cell viability to $75.9 \pm 3.7\%$ (from $87.1 \pm 1.7\%$ in 10 μ M Rg₁ group, $P<0.05$,

$n=12$, Fig. 1A) and increased LDH release to 279.5 ± 58.7 U/ml/min (from 100.5 ± 20.4 U/ml/min in 10 μ M Rg₁ group, $n=6$, $P<0.05$, Fig. 1B).

3.2. Protective effect of Rg₁ on hippocampal slice subjected to oxygen/glucose deprivation

To further assess the protective effect of Rg₁, we measured electrical activities in hippocampal slices. As illustrated in the upper panel in Fig. 2A, orthodromic population spikes in the control slices were depressed progressively and disappeared during the exposure of oxygen/glucose deprivation. In addition, in all control slices we observed a hypoxic injury potential (Fairchild et al., 1988), which occurred at about 8–12 min after the beginning of oxygen/glucose deprivation and subsided within 1–3 min (Fig. 2A). After 1-h reoxygenation, the orthodromic population spikes recovered with mean amplitude of only $5.4 \pm 5.4\%$ of that before oxygen/glucose deprivation. When Rg₁ (60 μ M) was added to the bath solution, however, the orthodromic population spikes were inhibited initially before oxygen/glucose deprivation in 5 of 6 slices tested (Fig. 2A). Rg₁ induced-inhibition was reversible as the orthodromic population spikes recovered after the removal of Rg₁ (data not shown). In the presence of Rg₁, at 60 μ M in particular, the occurring rate of hypoxic injury potential was reduced from 100% in control ($n=7$) to 50% ($P<0.05$, $n=6$, Fig. 2B), and the orthodromic population spikes, after 1-h reoxygenation, recovered significantly better ($89.8 \pm 31.0\%$ in Rg₁ at 60 μ M, $n=6$) than that of the control group ($5.4 \pm 5.4\%$, $n=7$, $P<0.05$, Fig. 2B).




Fig. 4. Nissl staining indicates reduced neuronal loss by ginsenoside Rg₁ in the cerebral cortex of rat after middle cerebral artery occlusion (MCAO). A, examples of Nissl stained neurons show that MCAO significantly reduced the cell number (center), comparing to the sham group (left panel). MCAO-induced cell loss was significantly blunted by Rg₁ pretreatment (right panel). Scale bar=20 μ m. B, mean values (\pm S.D.) of cell counting (from 6 rats). Cell number was counted in one vision under microscope ($\times 400$). **, $P<0.01$, vs sham (sham-operated); $^{\Delta\Delta}$, $P<0.01$, vs MCAO and sham.




Fig. 5. Ginsenoside Rg₁ inhibits positive expression of activated caspase-3 in the cerebral cortex of rats after middle cerebral artery occlusion (MCAO). A, examples show that MCAO significantly increased the number of cells with positive expression of activated caspase-3 (center), comparing to the sham group (left panel). MCAO-induced increase in the expression of activated caspase-3 was significantly inhibited by Rg₁ pretreatment (right panel). Positive cells were stained deeply as brown. Scale bar=20 μ m. B, mean values of positive expression cell counting ($n=6$). Cell number was counted in one vision under microscope ($\times 400$). **, $P<0.01$, vs sham (sham-operated); $\Delta\Delta$, $P<0.01$, vs MCAO and sham.

3.3. Protective effect of Rg₁ on rat brain subjected to middle cerebral artery occlusion

For another index of the protective effect of Rg₁, we examined the influence of Rg₁ on ischemic brain tissue. Rats displayed some functional deficits in neurology after middle cerebral artery occlusion. The neurology deficit score was respectively 2.5 ± 0.55 at 2 h and 2.83 ± 0.75 at 24 h (Fig. 3A). However, the neurology deficit score was reduced significantly at 24 h after middle cerebral artery occlusion in the group of rats treated with Rg₁ (1.33 ± 0.82 , $n=16$, $P<0.05$, Fig. 3A). Cerebral damage area was measured according to images of MRI at 4 h to 120 h after middle cerebral artery occlusion. With the damage area of the rat brain divided into the cortical and subcortical parts, we found that the cortical damage area extended with time and reached the peak at 48 h after middle cerebral artery occlusion (272.8 ± 35.8 mm³ vs 153.8 ± 19.5 mm³ at 4 h, $n=4$, $P<0.05$, Fig. 3B). By contraries, the subcortical damage size did not change significantly with time (data not shown). The cerebral damage size was reduced markedly after Rg₁ treatment. This reduction was detected primarily in the cortical part and at all the time points examined, with the mean value of 141.3 ± 28.0 mm³ at 120 h in Rg₁ group (vs 209.5 ± 34.9 mm³ of control, $n=4$, $P<0.05$, Fig. 3B).

We next compared the number of neuronal cells in parietal cortex in the border of the infarct area with Nissl staining. As illustrated in Fig. 4A and B, in the sham-operated group, the number of neuronal cells was 132.5 ± 9.0 , which was significantly reduced to 50.7 ± 6.6 after middle cerebral artery

occlusion ($n=6$, $P<0.01$, Fig. 4B). When the rats were treated with Rg₁, the number of neurons in the same brain area was elevated to 91.5 ± 7.5 ($n=6$, $P<0.01$, Fig. 4B).

3.4. Inhibition of Rg₁ on activated caspase-3 expression of the brain after middle cerebral artery occlusion

In order to evaluate the effect of Rg₁ on neuronal apoptosis after middle cerebral artery occlusion, the expression of activated caspase-3 was examined with immunohistochemistry in parietal cortex in the border of the infarct area (Fig. 5A). The number of caspase-3 positive neurons was increased from 7.7 ± 1.6 in sham-operated group to 45.7 ± 6.4 after middle cerebral artery occlusion ($P<0.01$, Fig. 5B). In contrast, the number of caspase-3 positive neurons in the same brain area was decreased to 25.7 ± 3.0 by Rg₁ treatment ($P<0.01$, Fig. 5B).

3.5. Inhibition of Rg₁ on oxygen/glucose deprivation-induced Ca²⁺ influx

We next determined calcium influx with laser confocal microscopy. As illustrated in Fig. 6A, Ca²⁺ influx of cultured hippocampal neurons was increased greatly after oxygen/glucose deprivation. Fig. 6B shows that a 10-min oxygen/glucose deprivation increased Ca²⁺ influx by $73.5 \pm 5.3\%$. This increase




Fig. 6. Ginsenoside Rg₁ inhibits Ca²⁺ influx in cultured hippocampal neurons deprived of oxygen/glucose (OGD). A, examples show that Ca²⁺ fluorescence intensity was significantly increased after OGD for 5 (central panel) and 10 min (right panel). These changes were not observed in neurons perfused with Ca²⁺ free solution, or treated with Rg₁ (60 μ M). Scale bar=15 μ m. B, mean values of four different treatments ($n=7$). **, $P<0.01$, vs OGD; Δ , $P<0.05$, vs Rg₁ at 10 μ M.

was inhibited remarkably (Fig. 6B) in the presence of Rg₁ (10 μ M, to $35.5 \pm 6.5\%$, $n=7$, $P<0.01$ and 60 μ M to, $16.4 \pm 4.3\%$, $n=7$, $P<0.01$) or in the absence of extracellular Ca²⁺ (Ca²⁺ free, to $4.5 \pm 2.6\%$, $n=7$, $P<0.01$).

3.6. Inhibition of Rg₁ on high K⁺-elicited Ca²⁺ influx

The above result indicates that Rg₁ reduces Ca²⁺ influx induced by oxygen/glucose deprivation. In an attempt to determine the mechanism underlying this phenomenon, we conducted the following experiments. Ca²⁺ influx was enhanced prominently when KCl (50 mM) was infused to the cultured hippocampal neurons (Fig. 7A and B). This enhancement was inhibited dose-dependently by nifedipine (at 0.2 μ M and 2 μ M, $P<0.01$, Fig. 7A and B), indicating that the Ca²⁺ influx was mediated by the L-type voltage-dependent Ca²⁺ channels. When Rg₁ was administered (1 nM–100 μ M), high K⁺-elicited Ca²⁺ influx was diminished as a function of Rg₁ concentrations, with the maximal inhibition by Rg₁ at 100 μ M (Fig. 7A and B). The mean (\pm S.D.) values of Ca²⁺ influx elevation in KCl, Rg₁ (10 μ M) and nifedipine (2 μ M) groups were $115.6 \pm 9.7\%$ ($n=8$), $39.2 \pm 8.2\%$ ($n=8$) and $31.1 \pm 4.3\%$ ($n=8$), respectively (Fig. 7B).

3.7. Inhibition of Rg₁ on NMDA-elicited Ca²⁺ influx

An addition of NMDA (1 mM) to the cultured hippocampal neurons remarkably elicited Ca²⁺ influx (Fig. 8A and B). This effect of NMDA was blocked dose-dependently by AP-4 or MK-801, the NMDA receptor antagonists, or by removing Ca²⁺ from




Fig. 7. Ginsenoside Rg₁ dose-dependently inhibits KCl-induced Ca²⁺ influx in cultured hippocampal neurons ($n=8$). A, KCl (50 mM)-induced Ca²⁺ influx or co-applied with Rg₁ (from 1 nM to 100 μ M, as indicated), as well as nifedipine (0.2 and 2 μ M, respectively, as indicated), an antagonist of L-type voltage-dependent Ca²⁺ channels. Scale bar was shown at the right lower side. B, mean values of all points after use of KCl of each curve in Fig. 7A. **, $P<0.01$, vs KCl; Δ , $P<0.05$, $\Delta\Delta$, $P<0.01$, vs Rg₁ at 1 nM.




Fig. 8. Ginsenoside Rg₁ dose-dependently inhibits NMDA-induced Ca²⁺ influx in cultured hippocampal neurons ($n=8$). A, NMDA (1 mM)-induced Ca²⁺ influx without and with the co-application of Rg₁ (at the indicated concentrations) and MK-801 and AP-4, the two antagonists of NMDA receptors. Rg₁ or each antagonist of NMDA receptors was applied simultaneously with NMDA to neurons. Scale bar was shown at the right lower side. B, mean values of all points after use of NMDA of each curve in Fig. 8A. **, $P<0.01$, vs NMDA; Δ , $P<0.05$, $\Delta\Delta$, $P<0.01$, vs Rg₁ at 100 nM; #, $P<0.01$, vs Rg₁ at other concentrations. Note that NMDA-induced Ca²⁺ influx was inhibited almost completely in the absence of Ca²⁺ in the medium (Ca²⁺ free).

the extracellular solution ($P<0.01$, Fig. 8A and B). The NMDA-elicited Ca²⁺ influx was reduced dose-dependently by Rg₁ (from 100 nM to 1 mM, Fig. 8A and B). The mean values of Ca²⁺ influx elevation in NMDA, Rg₁ (10 μ M), MK-801 (10 μ M), AP-4 (1 mM) and Ca²⁺ free groups ($n=8$) were $141.0 \pm 5.9\%$, $88.8 \pm 7.3\%$, $7.2 \pm 4.4\%$, $38.4 \pm 11.7\%$ and $15.6 \pm 12.1\%$, respectively (Fig. 8B).

4. Discussion

The present study in rats provided the first evidence that ginsenoside Rg₁ could protect neurons from damage induced by hypoxic–ischemic insults. We found that Rg₁ improved neuronal viability and reduced LDH release in cultured hippocampal neurons after oxygen/glucose deprivation. With Rg₁ treatment, hypoxic injury potential appeared less frequently, and the orthodromic population spike recovered better than that in the control hippocampal slices after oxygen/glucose deprivation. In addition, in *in vivo* experiments, Rg₁ decreased the neurology deficit score of rats 24 h after middle cerebral artery occlusion, indicating a promoting effect of Rg₁ on the recovery of the neurological function. Moreover, Rg₁ reduced the cerebral damage area on MRI, neuronal loss and expression of activated caspase-3 in the cerebral cortex. These results suggest a potential

application of Rg₁ as a neuroprotective agent for the treatment of ischemic cerebral stroke.

The protective effect of Rg₁ on neurons subjected to hypoxic–ischemic insults had been less studied before. This is likely because of the earlier negative results reported by Zhang and Liu (1996) in investigating the protective effect of Rg₁ (40 mg/kg, i.v.) on the rat brain subjected to both permanent and reversible (2-h) middle cerebral artery occlusion. Nevertheless, many researchers have found Rg₁ to be protective in other cell-damaging models in the recent decade. In a glutamate excitotoxic model, Liu and Zhang (1995) have observed that Rg₁ elevates the cell viability and reduces the LDH release of cortical neurons. Moreover, Liao et al. (2002) have documented that Rg₁ could protect the cultured spinal neurons from excitotoxicity induced by glutamate and kainic acid, as well as oxidative stress induced by H₂O₂. Li et al. (1997) and Li and Zhang (1997) have reported that Rg₁ inhibits the apoptosis of the cultured cortical neurons with serum withdrawal. Rudakewich et al. (2001) have reported that Rg₁ exerts a protective effect on the SN-K-SH cell line in a MPTP-induced cell toxicity model, but not on the beta-amyloid-induced cell death. In another report, Chen et al. (2003) have displayed that Rg₁ reduces the apoptosis of PC12 cells induced by exogenous dopamine. Recently, Leung et al. (2007) have shown that Rg₁ could protect nigral neurons from rotenone toxicity. The results of our present study are consistent with most of these reports.

In order to investigate the mechanisms underlying the protective effect of Rg₁ on the ischemic brain or oxygen/glucose-deprived neurons, we carried out additional *in vitro* experiments. We found that Rg₁ inhibited the increase of Ca²⁺ influx in hippocampal neurons subjected to oxygen/glucose deprivation. Furthermore, both high K⁺- and NMDA-induced Ca²⁺ influx was reduced dose-dependently by Rg₁. It is suggested that the neuroprotective effect of Rg₁ is probably mediated by the inhibition of Ca²⁺ influx through both NMDA receptor channels and L-type voltage-dependent Ca²⁺ channels, and the resultant reduction of intracellular free Ca²⁺. Similar inhibition of Ca²⁺ influx by Rg₁ has been observed by Liu and Zhang (1995) in a glutamate (0.5 mM) toxicity model of cultured hippocampal neurons of rats. In addition, other researchers have identified the inhibition of Ca²⁺ influx by other ginsenosides: inhibition of glutamate- or NMDA-gated Ca²⁺ influx in rat hippocampal neurons by Rg₃ (Kim et al., 2002, 2004; Lee et al., 2006a,b), Rh₁ (Lee et al., 2006a,b), Rh₂ (Lee et al., 2006a,b) and by total saponins (Kim et al., 2002); inhibition of voltage-dependent Ca²⁺ channels-mediated Ca²⁺ influx in neurons by total saponins (Kim et al., 2002; Lee et al., 2006a,b) and by some single ginsenosides (Lee et al., 2006a,b; Nah et al., 1995; Rhim et al., 2002). However, in contrast to our observation, Zhang and Liu (1996) have reported that Rg₁ at 40 mg/kg i.v. has neither any effect on Ca²⁺ accumulation in the infarct area and nor protective effect in rats subjected to permanent or 2-h middle cerebral artery occlusion. This inconsistency is possibly attributed to the differences in experimental conditions, including the induction of middle cerebral artery occlusion, sex and body weight of rats, dose, interval and route of use of Rg₁, as well as whether it is an *in vitro* or *in vivo* experiment.

It is generally believed that caspases are a family of intracellular proteins involved in the initiation and execution of cell apoptosis. The induction of apoptosis through extrinsic or intrinsic death mechanisms results in the activation of initiator caspases, where caspase-3 is a common and key executor caspase (Graham and Chen, 2001; Ashe and Berry, 2003). There are many evidence indicating that cerebral ischemia could induce the activation of caspases including caspase-3, up-regulation and activation of which have been proved to precede neuronal death. Caspase-mediated neuronal death after transient focal cerebral ischemia is more extensive than that after the permanent ischemia and may contribute to the delayed loss of neurons from the penumbral region of infarct (Graham and Chen, 2001; Love, 2003). In the present study, we documented neuronal loss and increased positive cells of activated caspase-3 expression in the border of the infarct area of the parietal cortex in rat after transient focal brain ischemia. These results are in line with those previously reviewed by Love (2003). After administration of Rg₁, the expression of activated caspase-3 was significantly inhibited. This anti-apoptotic effect of Rg₁ is consistent with the reports of several laboratories (Li et al., 1997; Li and Zhang, 1997). Generally, it is accepted that calcium overload is centrally involved in ischemic brain injury (Berliocchi et al., 2005), and activation of caspases is one of the downstream pathways of calcium signaling during ischemic cell death (White et al., 2000). Therefore, the inhibition of the caspase pathway could at least in part account for the neuroprotective effect of Rg₁ in the present study.

Ginsenosides have been identified to modulate the functions of many receptors and channels on neurons, and the present study extends these findings. However, the underlying mechanisms are still unclear. Given the structural similarity of ginsenosides with steroid hormones, Lee et al. (1997) and Chung et al. (1998) have investigated the interaction of Rg₁ with glucocorticoid receptor, and proved that Rg₁ is possibly a functional ligand of glucocorticoid receptor. On the basis of this, we applied RU486, an antagonist of glucocorticoid receptor, and observed its influence on the neuroprotective effect of Rg₁ in cultured rat hippocampal neurons deprived of oxygen and glucose. We found that RU486 blocked the effects of Rg₁ on neuronal viability and LDH release. This result suggests that the neuroprotective effect of Rg₁ is potentially mediated by the activation of glucocorticoid receptors. This is consistent with a recent report (Leung et al., 2007). It has been identified that the activation of glucocorticoid receptors could acutely inhibit NMDA receptor activity in the CA₁ area of the mouse hippocampal slices (Sato et al., 2004). Nevertheless, the same research group has reported an opposite result in rats (Takahashi et al., 2002). The differences in the experimental conditions of these two studies may contribute to the controversial results. Moreover, there are many controversies about the effect of glucocorticoid or its receptors in neuroprotection (Abraham et al., 2001; Anderson and Cranford, 1979). Therefore, more precise experiments are needed to clarify these issues.

In the present study, we found an interesting phenomenon, i.e., pretreatment with ginsenoside Rg₁ reversibly reduced the amplitude of orthodromic population spikes in hippocampal slices

before any other treatments. This inhibition has also been observed previously in our experiments upon the neuroprotective effect of total saponins of ginseng (Jiang et al., 2000, 2001) and ginsenoside Rb₁ (unpublished data). The orthodromic population spike is a field potential recorded extracellularly, a synchronous response of action potentials of many post-synaptic hippocampal neurons in CA₁ area. It is known that the synaptic transmission is herein mediated by the neurotransmitter glutamate (Amaral and Witter, 1989). Hence, it is suggested that ginsenoside Rg₁ could inhibit glutamatergic transmission. At present, the exact mechanisms of this inhibition are unclear. An inhibition of Rg₁ on NMDA receptors and L-type voltage-dependent Ca²⁺ channels found in the present study is potentially involved. Whether other pre-synaptic or post-synaptic mechanisms are attributable to this phenomenon warrants further study.

In conclusion, ginsenoside Rg₁ exerted a neuroprotective role on the oxygen/glucose-deprived hippocampal neurons and slices, as well as on the ischemic/reperfused brain in rats. This effect is probably mediated by the activation of glucocorticoid receptors, the inhibition of Ca²⁺ influx through both NMDA receptor channels and L-type voltage-dependent Ca²⁺ channels, and the resultant reduction of intracellular free Ca²⁺. As a result, neuronal death including apoptotic cell death is diminished.

Acknowledgements

This study was supported by grants from the Administration of Science and Technology of Jiangsu (Project No. BK2003036) and from the Administration of Education of Jiangsu (Projects No. 03KJD310185 and KJS02052), Jiangsu Province, China. We were grateful to Prof. T.Y. Zhang and Dr. W. Hu of the Jiangsu Key Laboratory of Neuroregeneration of our university for technical assistance in the measurement of intracellular free Ca²⁺. We are grateful to Dr. J.H. Ye of the University of Medicine and Dentistry of New Jersey of USA for constructive discussion on this work.

References

Abraham, I.M., Harkany, T., Horvath, K.M., Luiten, P.G., 2001. Action of glucocorticoids on survival of nerve cells: promoting neurodegeneration or neuroprotection? *J. Neuroendocrinol.* 13, 749–760.

Amaral, D.G., Witter, M.P., 1989. The three dimensional organization of the hippocampal formation: a review of anatomical data. *Neuroscience* 31, 571–591.

Anderson, D.C., Cranford, R.E., 1979. Corticosteroids in ischemic stroke. *Stroke* 10, 68–71.

Ashe, P.C., Berry, M.D., 2003. Apoptotic signaling cascades. *Prog. Neuro-Psychopharmacol. Biol. Psychiatry* 27, 199–214.

Attele, A.S., Wu, J.A., Yuan, C.S., 1999. Ginseng pharmacology: multiple constituents and multiple actions. *Biochem. Pharmacol.* 58, 1685–1693.

Berliocchi, L., Bano, D., Nicotera, P., 2005. Ca²⁺ signals and death programmes in neurons. *Philos. Trans. R. Soc. Lond., B* 360, 2255–2258.

Chen, X.C., Zhu, Y.G., Zhu, L.A., Huang, C., Chen, Y., Chen, L.M., Fang, F., Zhou, Y.C., Zhao, C.H., 2003. Ginsenoside Rg₁ attenuates dopamine-induced apoptosis in PC12 cells by suppressing oxidative stress. *Eur. J. Pharmacol.* 473, 1–7.

Cheng, Y.D., Al-Khoury, L., Zivin, J.A., 2004. Neuroprotection for ischemic stroke: two decades of success and failure. *NeuroRx* 1, 36–45.

Chung, E., Lee, K.Y., Lee, Y.J., Lee, Y.H., Lee, S.K., 1998. Ginsenoside-Rg₁ down-regulates glucocorticoid receptor and displays synergistic effects with cAMP. *Steroids* 63, 421–424.

Curry, S.H., 2003. Why have so many drugs with stellar results in laboratory stroke models failed in clinical trials? A theory based on allometric relationships. *Ann. N.Y. Acad. Sci.* 993, 69–74.

Fairchild, M.D., Parsons, J.E., Wasterlain, C.G., Rinaldi, P.C., Wallis, R.A., 1988. A hypoxic injury potential in the hippocampal slice. *Brain Res.* 453, 357–361.

Gerriets, T., Li, F., Silva, M.D., Meng, X., Brevard, M., Sotak, C.H., Fisher, M., 2003. The macrosphere model: evaluation of a new stroke model for permanent middle cerebral artery occlusion in rats. *J. Neurosci. Methods* 122, 201–211.

Gladstone, D.J., Black, S.E., Hakim, A.M., 2002. Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. *Stroke* 33, 2123–2136.

Graham, S.H., Chen, J., 2001. Programmed cell death in cerebral ischemia. *J. Cereb. Blood Flow Metab.* 21, 99–109.

Heiland, S., Reith, W., Forsting, M., Sartor, K., 1997. Perfusion-weighted magnetic resonance imaging using a new gadolinium complex as contrast agent in a rat model of focal cerebral ischemia. *J. Magn. Reson. Imaging* 7, 1109–1115.

Ji, Y.C., Kim, Y.B., Park, S.W., Hwang, S.N., Min, B.K., Hong, H.J., Kwon, J.T., Suk, J.S., 2005. Neuroprotective effect of ginseng total saponins in experimental traumatic brain injury. *J. Korean Med. Sci.* 20, 291–296.

Jiang, S., Jiang, Z.L., 2003. Protective effect of ginsenoside Rb₁ on ischemic brain injury in rat. *J. Apoplexy Nerv. Dis.* 20 (5), 415–417.

Jiang, Z.L., Chen, Y.R., Zhou, C., Shi, J.S., Duan, S.M., 2001. Glutamate-related mechanisms of ginsenosides against hypoxic–ischemic brain damage. *Chin. J. Appl. Physiol.* 17, 105–108.

Jiang, Z.L., Wu, X.M., Jin, S.Y., Chen, Y.P., Zhuang, J., 2000. Effect of ginsenosides on hypoxic brain injury in hippocampal slice. *Chin. J. Nat. Med.* 7, 28–32.

Jonas, S., Aiyagari, V., Vieira, D., Figueroa, M., 2001. The failure of neuronal protective agents versus the success of thrombolysis in the treatment of ischemic stroke: the predictive value of animal models. *Ann. N.Y. Acad. Sci.* 939, 257–267.

Kiefer, D., Pantuso, T., 2003. *Panax ginseng*. *Am. Fam. Phys.* 68, 1539–1542.

Kim, S., Rhim, H., 2004. Ginsenosides inhibit NMDA receptor-mediated epileptic discharges in cultured hippocampal neurons. *Arch. Pharm. Res.* 27, 524–530.

Kim, Y.C., Kim, S.R., Markelonis, G.J., Oh, T.H., 1998. Ginsenosides Rb₁ and Rg₃ protect cultured rat cortical cells from glutamate-induced neurodegeneration. *J. Neurosci. Res.* 4, 426–432.

Kim, S., Ahn, K., Oh, T.H., Nah, S.Y., Rhim, H., 2002. Inhibitory effect of ginsenosides on NMDA receptor-mediated signals in rat hippocampal neurons. *Biochem. Biophys. Res. Commun.* 296, 247–254.

Kim, S., Kim, T., Ahn, K., Park, W.K., Nah, S.Y., Rhim, H., 2004. Ginsenosides Rg₃ antagonizes NMDA receptors through a glycine modulatory site in rat cultured hippocampal neurons. *Biochem. Biophys. Res. Commun.* 323, 416–424.

Kim, J.H., Cho, S.Y., Lee, J.H., Jeong, S.M., Yoon, I.S., Lee, B.H., Lee, J.H., Pyo, M.K., Lee, S.M., Chung, J.M., Kim, S., Rhim, H., Oh, J.W., Nah, S.Y., 2007. Neuroprotective effects of ginsenoside Rg₃ against homocysteine-induced excitotoxicity in rat hippocampus. *Brain Res.* 1136, 190–199.

Lee, Y.J., Chung, E., Lee, K.Y., Lee, Y.H., Huh, B., Lee, S.K., 1997. Ginsenoside-Rg₁, one of the major active molecules from *Panax ginseng*, is a functional ligand of glucocorticoid receptor. *Mol. Cell. Endocrinol.* 133, 135–140.

Lee, J.H., Kim, S.R., Bae, C.S., Kim, D.H., Hong, H.N., Nah, S.Y., 2002. Protective effect of ginsenosides, active ingredients of *Panax ginseng*, on kainic acid-induced neurotoxicity in rat hippocampus. *Neurosci. Lett.* 325, 129–133.

Lee, E., Kim, S., Chung, K.C., Choo, M.K., Kim, D.H., Nam, G., Rhim, H., 2006a. 20(S)-ginsenoside Rh₂, a newly identified active ingredient of ginseng, inhibits NMDA receptors in cultured rat hippocampal neurons. *Eur. J. Pharmacol.* 536, 69–77.

Lee, J.H., Jeong, S.M., Kim, J.H., Lee, B.H., Yoon, I.S., Lee, J.H., Choi, S.H., Lee, S.M., Park, Y.S., Lee, J.H., Kim, S.S., Kim, H.C., Lee, B.Y., Nah, S.Y., 2006b. Effects of ginsenosides and their metabolites on voltage-dependent Ca²⁺ channel subtypes. *Mol. Cells* 21, 52–62.

Leung, K.W., Yung, K.K.L., Mak, N.K., Chan, Y.S., Fan, T.P., Wong, R.N.S., 2007. Neuroprotective effects of ginsenoside-Rg₁ in primary nigral neurons against rotenone toxicity. *Neuropharmacology* 52, 827–835.

- Li, J.Q., Zhang, J.T., 1997. Inhibition of apoptosis by ginsenoside Rg₁ in cultured cortical neurons. *Chin. Med. J.* 110 (7), 535–539.
- Li, J.Q., Zhang, X.G., Zhang, J.T., 1997. Study on the anti-apoptotic mechanism of ginsenoside Rg₁ in cultured cortical neurons. *Acta Pharm. Sin.* 32 (6), 406–410.
- Liao, B., Newmark, H., Zhou, R., 2002. Neuroprotective effects of ginseng total saponin and ginsenosides Rb₁ and Rg₁ on spinal cord neurons *in vitro*. *Exp. Neurol.* 173, 224–234.
- Lim, J.H., Wen, T.C., Matsuda, S., Tanaka, J., Maeda, N., Peng, H., Aburaya, J., Ishihara, K., Sakanaka, M., 1997. Protection of ischaemic hippocampal neurons by ginsenosides Rb₁, a main ingredient of ginseng root. *Neurosci. Res.* 28, 191–200.
- Liu, M., Zhang, J.T., 1995. Protective effects of ginsenoside Rb₁ and Rg₁ on cultured hippocampal neurons. *Acta Pharm. Sin.* 30 (9), 674–678.
- Love, S., 2003. Apoptosis and brain ischaemia. *Prog. Neuro-Psychopharmacol. Biol. Psychiatry* 27, 267–282.
- Nah, S.Y., Park, H.J., McCleskey, E.W., 1995. A trace component of ginseng that inhibits Ca²⁺ channels through a pertussis toxin-sensitive G protein. *Proc. Natl. Acad. Sci. U. S. A.* 92, 8739–8743.
- Rhim, H., Kim, H., Lee, D.Y., Oh, T.H., Nah, S.Y., 2002. Ginseng and ginsenoside Rg₃, a newly identified active ingredient of ginseng, modulate Ca²⁺ channel currents in rat sensory neurons. *Eur. J. Pharmacol.* 436, 151–158.
- Rudakewich, M., Ba, F., Benishin, C.G., 2001. Neurotrophic and neuroprotective actions of ginsenosides Rb₁ and Rg₁. *Planta Med.* 67, 533–537.
- Sato, S., Osanai, H., Monma, T., Harada, T., Hirano, A., Saito, M., Kawato, S., 2004. Acute effect of corticosterone on *N*-methyl-D-aspartate receptor-mediated Ca²⁺ elevation in mouse hippocampal slices. *Biochem. Biophys. Res. Commun.* 321, 510–513.
- Saver, J.L., Kidwell, C., Eckstein, M., Starkman, S., 2004. Prehospital neuroprotective therapy for acute stroke: results of the field administration of stroke therapy-magnesium (FAST-MAG) pilot trial. *Stroke* 35, e106–e108.
- Takahashi, T., Kimoto, T., Tanabe, N., Hattori, T., Yasumatsu, N., Kawato, S., 2002. Corticosterone acutely prolonged *N*-methyl-D-aspartate receptor-mediated Ca²⁺ elevation in cultured rat hippocampal neurons. *J. Neurochem.* 83, 1441–1451.
- Tian, J., Fu, F., Geng, M., Jiang, Y., Yang, J., Jiang, W., Wang, C., Liu, K., 2005. Neuroprotective effect of 20(*S*)-ginsenoside Rg₃ on cerebral ischemia in rats. *Neurosci. Lett.* 374, 92–97.
- Van Kampen, J., Robertson, H., Hagg, T., Drobitch, R., 2003. Neuroprotective actions of the ginseng extract G115 in two rodent models of Parkinson's disease. *Exp. Neurol.* 184, 21–29.
- Wen, T.C., Yoshimura, H., Matsuda, S., Lim, J.H., Sakanaka, M., 1996. Ginseng root prevents learning disability and neuronal loss in gerbils with 5-minute forebrain ischaemia. *Acta Neuropathol.* 91, 15–22.
- White, B.C., Sullivan, J.M., DeGracia, D.J., O'Neil, B.J., Neumar, R.W., Grossman, L.I., Rafols, J.A., Krause, G.S., 2000. Brain ischemia and reperfusion: molecular mechanisms of neuronal injury. *J. Neurol. Sci.* 179, 1–33.
- Zhang, Y.G., Liu, T.P., 1996. Influences of ginsenosides Rb₁ and Rg₁ on reversible focal brain ischemia in rats. *Acta Pharmacol. Sin.* 17 (1), 44–48.

Further reading

- Lee, J.H., Jeong, S.M., Lee, B.H., Noh, H.S., Kim, B.K., Kim, J.I., Rhim, H., Kim, H.C., Kim, K.M., Nah, S.Y., 2004. Prevention of ginsenoside-induced desensitization of Ca²⁺-activated Cl[−] current by microinjection of inositol hexakisphosphate in *Xenopus laevis* oocytes: involvement of GRK2 and beta-arrestin I. *J. Biol. Chem.* 279, 9912–9921.